- Home
- OPRX vs ARMP Comparison
OPRX vs ARMP Comparison
Compare OPRX & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OPRX | ARMP |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.4M | 383.7M |
| IPO Year | 2008 | 1996 |
Fundamental Metrics
Financial Performance| Metric | OPRX | ARMP |
|---|---|---|
| Price | $6.69 | $11.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $16.67 | $15.00 |
| AVG Volume (30 Days) | ★ 488.0K | 28.4K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 124.55 | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $109,429,000.00 | N/A |
| Revenue This Year | $3.88 | N/A |
| Revenue Next Year | $8.49 | N/A |
| P/E Ratio | $25.19 | ★ N/A |
| Revenue Growth | ★ 18.78 | N/A |
| 52 Week Low | $5.54 | $0.90 |
| 52 Week High | $22.25 | $13.75 |
Technical Indicators
Market Signals| Indicator | OPRX | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 44.78 | 64.88 |
| Support Level | $5.74 | $5.14 |
| Resistance Level | $7.47 | $12.11 |
| Average True Range (ATR) | 0.46 | 1.13 |
| MACD | 0.15 | 0.23 |
| Stochastic Oscillator | 48.37 | 94.67 |
Price Performance
Historical ComparisonAbout OPRX OptimizeRx Corporation
OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.